Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

November 14, 2016

Conditions
Acute Myocardial Infarction
Interventions
BIOLOGICAL

Allogeneic human cardiac stem cells (CSCs)

Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.

OTHER

Human Serum Albumin-HSA 5%

Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.

Trial Locations (1)

28760

Coretherapix (Tigenix Group), Tres Cantos

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

European Commission

OTHER

collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

collaborator

Saint-Louis Hospital, Paris, France

OTHER

collaborator

Hospital General Universitario Gregorio Marañon

OTHER

collaborator

Complejo Hospitalario de Navarra

OTHER

collaborator

Hospital Clínico Universitario de Valladolid

OTHER

collaborator

Hospital Donostia

OTHER

collaborator

Hospital Clínico Universitario de Valencia

OTHER

collaborator

University of Salamanca

OTHER

collaborator

Hospital Universitario Virgen de la Victoria

OTHER

lead

Coretherapix

INDUSTRY